Patients from 22+ countriesPlan your visit →
lutetium-therapy
Patient Journey · 17 Sept 2026

Erectile Dysfunction After Lu-177 PSMA Therapy

Erectile dysfunction is one of the most common concerns men with mCRPC raise during Lu-177 PSMA therapy - but it is rarely the therapy itself that is the primary cause. This article explains why ED is so widespread at this stage, what a realistic recovery timeline looks like, and what management strategies may help protect intimacy.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 17 Sept 2026
Erectile Dysfunction After Lu-177 PSMA Therapy

If you have metastatic castration-resistant prostate cancer (mCRPC) and are receiving or considering lutetium Lu-177 vipivotide tetraxetan - the targeted radioligand therapy known by the brand name Pluvicto - you may wonder what this treatment means for your sex life. It is one of the most common concerns men have at this stage, and one of the least often raised with a doctor.

This article is for men with mCRPC receiving Lu-177 PSMA therapy. It does not address neuroendocrine tumour patients. It covers why erectile dysfunction (ED) is so common at this stage, what role Lu-177 PSMA therapy plays, what recovery looks like, and what management options may help.

Why Is Erectile Dysfunction So Common at the mCRPC Stage?

By the time a man reaches the mCRPC stage and qualifies for Lu-177 PSMA therapy, he has typically received several rounds of cancer treatment. This often includes androgen deprivation therapy (ADT), which lowers testosterone to very low levels. It may also include surgery to remove the prostate, pelvic radiation, and chemotherapy. Each treatment can affect sexual function differently, and their effects add up over time.

ADT continues during Lu-177 PSMA therapy. Testosterone plays a central role in sex drive, the ability to achieve an erection, and orgasm. When testosterone stays suppressed for a long time, the body's sexual response changes in significant ways. Research on ADT shows that the therapy reduces libido, erection quality, and ejaculatory capacity in most men, with effects that may get worse the longer ADT continues. Some men keep some sexual response; others experience a big drop in desire.

If you had surgery or pelvic radiation earlier in your cancer treatment, those treatments may have already damaged the nerves and blood vessels that support erections. For many men at the mCRPC stage, some degree of ED is present before Lu-177 PSMA therapy even begins. Understanding this baseline matters when you set realistic expectations about what comes next.

What Role Does Lu-177 PSMA Therapy Actually Play?

Lu-177 PSMA therapy targets the PSMA protein on prostate cancer cells and sends radiation directly to those cells. This is very different from external beam radiation therapy, which delivers radiation to a wide pelvic area and can damage the nerves and blood vessels that support erections over time.

Lu-177 PSMA does not deliver that kind of wide pelvic dose. Its effects on erectile function are mostly indirect - through fatigue, through the continued presence of ADT, and through the stress of being in active cancer treatment.

Safety data from the VISION trial - the Phase 3 study that supported FDA approval of lutetium Lu-177 vipivotide tetraxetan - show that fatigue is among the most commonly reported side effects of the therapy. Fatigue can reduce your energy for physical intimacy, affect your mood, and lower your interest in sex during and shortly after each treatment cycle. These effects are usually worst in the days after an infusion and tend to ease in the weeks between cycles.

Nausea and dry mouth are also common during treatment. Together with fatigue, they create a general sense of feeling unwell that makes sexual activity harder during the active treatment period.

If you are preparing for your first infusion and want to understand what the experience is like, our guide on what to expect in your first Lu-177 PSMA cycle walks through the process step by step.

What the Evidence Shows on Quality of Life

The VISION trial measured health-related quality of life alongside survival outcomes. The analysis found that patients receiving lutetium Lu-177 vipivotide tetraxetan plus standard of care had quality-of-life scores that stayed the same or improved compared to those receiving standard of care alone, including on pain and overall health. Sexual function was not the main focus of these quality-of-life measures, but the broader finding - that the treatment does not seem to make patients feel much worse overall - is useful context when you decide whether to proceed.

Recovery Timeline: An Honest Picture

How much erectile function can recover at the mCRPC stage depends on how long ADT has been used, what prior treatments have affected pelvic anatomy, and individual factors including age and baseline function before treatment.

For men who stay on continuous ADT - which is standard in mCRPC - a return to pre-treatment erectile function is not typically expected while ADT continues. This is not a consequence of Lu-177 therapy specifically; it reflects what testosterone suppression does to the body.

During the Lu-177 treatment period itself, most men describe a pattern. Fatigue and physical discomfort are worst in the days after each infusion and ease as the weeks pass. Sexual interest and physical energy tend to follow that same pattern - lower near infusion time, somewhat better in the weeks between cycles.

If your oncologist changes your ADT approach at some point - a clinical decision made with a full picture of your cancer status - some men experience a gradual partial return of libido and erection over months. This varies widely and is not guaranteed. It is a conversation worth having with your oncologist when the time is right.

Our article on what to expect 3-6 months after Lu-177 PSMA therapy covers the broader recovery period, including how your team monitors response and what changes are worth tracking over time.

Management Strategies That May Help

There is no single fix for ED in advanced prostate cancer. But there are several approaches a urologist or sexual health specialist may consider, depending on your situation and overall health.

Oral medications

A class of medications called PDE5 inhibitors works by increasing blood flow to the penis. They do not create desire on their own, but they may support erection when you have some sexual interest. They are not suitable for everyone - particularly men with certain heart conditions or on specific medications - so you need a medical review before starting them. Research on penile rehabilitation suggests PDE5 inhibitors are a reasonable first option to try for many men managing ED after prostate cancer treatment, though their effect varies from person to person.

Vacuum erection devices

A vacuum erection device (VED) is a cylinder placed around the penis that uses gentle suction to draw blood in. A constriction ring then holds the erection in place. VEDs are non-invasive, drug-free, and available without a prescription in many countries. They require some practice to use comfortably, and many couples find it helpful to learn how to use them together.

Penile injections

Injection therapy involves placing medication directly into the base of the penis to produce an erection. It can work when oral medications have not helped. It requires training from a urologist and is not the right choice for every man, but it gives a meaningful option to those who need it.

Penile implants

A surgically placed penile implant is a more permanent solution that some men consider after other approaches have not met their needs. In the mCRPC setting, this option requires careful discussion between your oncologist and urologist to determine whether the timing is appropriate given your cancer status and overall health.

Psychosexual counseling

ED in advanced cancer has both physical and emotional roots. Anxiety about the cancer, grief about changes in physical function, and worry about being less desirable to a partner can all worsen ED - and ED can in turn generate more anxiety. A therapist with experience in oncology and sexual health can help you work through that. The Prostate Cancer Foundation's guidance on sex and intimacy after prostate cancer is a good starting point that addresses both the physical options and the emotional issues couples face.

Stress and disrupted sleep also hurt sexual wellbeing during long treatment courses. Managing them through counseling, gentle physical activity, or structured daily routines can make a real difference to how you feel overall.

Intimacy Beyond Erection

Intimacy in a relationship does not depend on penetrative sex. Touch, closeness, shared attention, and physical affection all carry real meaning - often more than couples realize until something changes.

Many couples who work through ED after a prostate cancer diagnosis describe building a different kind of intimacy - one based on honest communication rather than unspoken expectation. This often means saying what feels good, what each person needs, and what sex means to each person beyond physical performance.

Partners are directly affected by these changes and should be included in conversations with the care team - not left to manage their own feelings about the shift alone. If these conversations feel hard to start, a couples counsellor with oncology experience can help both of you find a way in.

Talking to Your Care Team

Many men avoid raising ED with their oncologist, assuming it is not a medical priority or that nothing can be done. Both assumptions are worth questioning. Your care team expects these questions. They can refer you to a urologist or sexual health specialist, help identify whether any medications or treatment decisions are contributing to the problem, and guide you on what options fit your overall health.

Raising the topic early - ideally before Lu-177 PSMA therapy begins - gives your team a baseline to work from and opens the conversation before distress sets in. If you are still deciding whether to proceed with Lu-177 PSMA therapy and want to weigh quality-of-life factors alongside the clinical data, you can ask whether Lu-177 fits your case through Art of Healing Cancer for a specialist review of your situation before committing to a plan.

For younger men who want to consider fertility alongside sexual function, our article on Lu-177 PSMA therapy timing and fertility in men under 60 addresses those specific concerns in detail.

When to Talk to Your Doctor

Speak with your oncologist or urologist if ED is causing significant distress for you or your partner; if you have tried a management approach and it has not helped; if you notice new physical symptoms such as pain or numbness alongside ED; or if the emotional weight of sexual changes is affecting your mood, relationship, or daily life in a serious way. A referral to a sexual health specialist is a normal part of cancer care - not a last resort.

If you are considering Lu-177 PSMA therapy or want an eligibility review, you can send your scan results and medical history to the team through the Lutetium Therapy contact form. If Lu-177 is not the right fit for your case, the team can offer a second opinion on what alternatives may be worth discussing with your oncologist.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Does Lu-177 PSMA therapy itself cause erectile dysfunction?

Lu-177 PSMA therapy is not typically a direct cause of erectile dysfunction in the way that radical prostatectomy or pelvic external beam radiation can be. The therapy targets PSMA-expressing cancer cells rather than delivering a broad sustained dose to pelvic structures. The main drivers of ED at the mCRPC stage are androgen deprivation therapy, which continues during Lu-177 treatment, prior treatments such as surgery or radiation, and the general physical burden of advanced cancer. Fatigue from each treatment cycle can reduce energy and sexual interest, but this usually improves between cycles.

Will my erectile function improve after I finish Lu-177 PSMA therapy?

For men who remain on androgen deprivation therapy - standard in mCRPC - a full return to pre-treatment levels of erectile function is not typically expected while ADT continues. Fatigue related to the treatment cycles tends to ease in the months after completing therapy, which may allow more energy for intimacy. Whether erectile function itself improves depends heavily on how long ADT has been in use, what prior treatments affected pelvic anatomy, and your individual baseline. Speak with your urologist about what recovery options are realistic in your specific situation.

Can I take medication for erectile dysfunction while on Lu-177 PSMA therapy?

Some medications used to treat ED may be appropriate for men receiving Lu-177 PSMA therapy, but this depends on your overall health, heart function, and other medications you are already taking. Do not start any ED medication without first discussing it with your oncologist or urologist. They can review your full picture and advise on the safest and most appropriate option for you.

How do I talk to my partner about sexual changes during cancer treatment?

Many couples find it helpful to name the changes early rather than letting silence build around them. You do not need a solution before starting the conversation. Letting your partner know that your interest in sex may change - and that this is a treatment effect rather than a reflection of how you feel about them - can relieve pressure on both sides. A therapist with experience in oncology and couples communication can help both of you work through these conversations if they feel difficult to begin on your own.

Are there non-medication options for managing ED during mCRPC treatment?

Yes. A vacuum erection device uses gentle suction to draw blood into the penis and can assist erection without any medication. Psychosexual counseling - both individual and couples - addresses the emotional and relational dimensions of ED. Staying physically active within your energy limits, managing stress, and supporting sleep quality may also improve sexual wellbeing indirectly. Your urologist can help you identify which combination of approaches is most appropriate for your situation.

Should I raise ED with my oncologist or a urologist?

Both can play a role. Your oncologist oversees the overall treatment plan and can help identify whether any treatment decisions are contributing to ED. A urologist - ideally one with experience in cancer-related sexual health - will have more specific expertise in physical management options such as medications, devices, or injection therapy. If you have not already been referred to a urologist as part of your mCRPC care, ask your oncologist for that referral.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Erectile Dysfunction After Lu-177 PSMA Therapy | lutetium-therapy